Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

被引：17

作者：

Fecher, Leslie A. ^{[1
]}

Flaherty, Keith T. ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2009年 / 7卷 / 03期

关键词：

Adjuvant; melanoma; interferon; pegylated; HIGH-RISK MELANOMA; ACTIVE SPECIFIC IMMUNOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; AMERICAN-JOINT-COMMITTEE; HIGH-DOSE INTERFERON; PHASE-III; METASTATIC MELANOMA; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; SURGICAL ADJUVANT;

D O I：

10.6004/jnccn.2009.0022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant therapy options for advanced melanoma in 2009 remain active observation, high-dose interferon, or clinical trial participation. Close observation is currently the only required adjuvant management, with the purpose of detecting the emergence of regional or metastatic disease early, when surgical management may still be possible. The National Comprehensive Cancer Network guidelines for the workup and,follow-up of all stages of melanoma must, be tailored to specific patients by the treating physician. This article explores the factors to consider when individualizing care within the scope of these guidelines. (JNCCN 2009;7:295-304)

引用

页码：295 / 304

页数：10

共 63 条

[1]

Agarwala S.S., 2007, J CLIN ONCOL, V25, P8510

[2] Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease [J].

Anaya, Daniel A. ;

Xing, Yan ;

Feng, Lei ;

Huang, Xuelin ;

Camacho, Luis H. ;

Ross, Merrick I. ;

Gershenwald, Jeffrey E. ;

Lee, Jeffrey E. ;

Mansfield, Paul F. ;

Cormier, Janice N. .

CANCER, 2008, 112 (09) :2030-2037

[3] Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group [J].

Atkins, Michael B. ;

Hsu, Jessie ;

Lee, Sandra ;

Cohen, Gary I. ;

Flaherty, Lawrence E. ;

Sosman, Jeffrey A. ;

Sondak, Vernon K. ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5748-5754

[4] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[5] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].

Balch, CM ;

Buzaid, AC ;

Soong, SJ ;

Atkins, MB ;

Cascinelli, N ;

Coit, DG ;

Fleming, ID ;

Gershenwald, JE ;

Houghton, A ;

Kirkwood, JM ;

McMasters, KM ;

Mihm, MF ;

Morton, DL ;

Reintgen, DS ;

Ross, MI ;

Sober, A ;

Thompson, JA ;

Thompson, JF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648

[6] Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma [J].

Ben-Porat, L ;

Panageas, KS ;

Hanlon, C ;

Pate, A ;

Halpern, A ;

Houghton, AN ;

Coit, D .

CANCER, 2006, 106 (01) :163-171

[7] Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases [J].

Berd, D ;

Maguire, HC ;

Schuchter, LM ;

Hamilton, R ;

Hauck, WW ;

Sato, T ;

Mastrangelo, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2359-2370

[8] Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine [J].

Berd, D ;

Sato, T ;

Maguire, HC ;

Kairys, J ;

Mastrangelo, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :403-415

[9] Treating cancer with PEG intron - Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation [J].

Bukowski, RM ;

Tendler, C ;

Cutler, D ;

Rose, E ;

Laughlin, MM ;

Statkevich, P .

CANCER, 2002, 95 (02) :389-396

[10] Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial [J].

Cascinelli, N ;

Belli, F ;

MacKie, RM ;

Santinami, M ;

Bufalino, R ;

Morabito, A .

LANCET, 2001, 358 (9285) :866-869

← 1 2 3 4 5 6 7 →